1 research outputs found
Hepatitis C Replication Inhibitors That Target the Viral NS4B Protein
We describe the preclinical development
and in vivo efficacy of a novel chemical series that inhibits hepatitis
C virus replication via direct interaction with the viral nonstructural
protein 4B (NS4B). Significant potency improvements were realized
through isosteric modifications to our initial lead <b>1a</b>. The temptation to improve antiviral activity while compromising
physicochemical properties was tempered by the judicial use of ligand
efficiency indices during lead optimization. In this manner, compound <b>1a</b> was transformed into (+)-<b>28a</b> which possessed
an improved antiviral profile with no increase in molecular weight
and only a modest elevation in lipophilicity. Additionally, we employed
a chimeric “humanized” mouse model of HCV infection
to demonstrate for the first time that a small molecule with high
in vitro affinity for NS4B can inhibit viral replication in vivo.
This successful proof-of-concept study suggests that drugs targeting
NS4B may represent a viable treatment option for curing HCV infection